Erythropoietin Improves Long-Term Outcomes in Patients with Acute Kidney Injury after Coronary Artery Bypass Grafting

Journal of Korean Medical Science, 05/21/2012

Erythropoietin (EPO) reduces all–cause–mortality and end stage renal disease in patients with acute kidney injury (AKI), largely due to the beneficial effect of EPO on recovery after AKI.

Print Article Summary Cat 2 CME Report